Survodutide: Benefits & Research
Part of the Survodutide Complete Guide
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
Weight Loss
Phase 2 trials demonstrated up to 18.7% body weight loss — comparable to or exceeding semaglutide. The dual GLP-1/glucagon mechanism provides weight loss through appetite suppression (GLP-1) and increased energy expenditure (glucagon).
MASH Improvement
The Phase 2 MASH trial published in NEJM showed survodutide significantly improved liver histology — achieving MASH resolution without worsening fibrosis in up to 83% of patients at the highest dose. The glucagon component drives hepatic lipid oxidation, directly addressing the liver fat accumulation underlying MASH.
Metabolic Benefits
Survodutide improved multiple metabolic parameters including HbA1c, liver enzymes (ALT), triglycerides, and waist circumference. The dual mechanism addresses both systemic (obesity) and organ-specific (liver) metabolic dysfunction.